‘Growth Strategies in Generics: Innovative and aggressive strategies and their impact on branded pharmaceuticals ’is a report which assesses the growth prospects of generic drugs in Europe and the US. The report gives a detailed analysis of the impact of new legislation, the strategies of the key players and market pressures on the generic and branded drug sectors. The generics market in both Europe and the US is highly dynamic. Growth is high, and forecast to continue strongly in the next five years as penetration of generics in pharmaceutical sales is still comparatively low in key markets such as the UK and France. At the same time, the distinctions between some generics companies and traditional, R&D-led pharmaceutical companies are blurring as generics companies move up-stream and invest in R&D while pharmaceutical companies such as Novartis, Sanofi and Merck retain successful generic subsidiaries. However, market saturation threatens to erode profit margins for generics companies as prices are forced lower, while manufacturers outside Europe and the US take an increasing market share. Identify the key trends in manufacturing, marketing, competitive structure profit margins and intellectual property in Europe and the US with the help of our latest report.
ISBN 1-84296-414-3
Published: July 2004 - Global. |
